Morten Holmström
Morten Holmström
National Center for Cancer Immune Therapy, Herlev Hospital, Denmark
Patvirtintas el. paštas
A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
JW Kjeldsen, CL Lorentzen, E Martinenaite, E Ellebaek, M Donia, ...
Nature medicine 27 (12), 2212-2223, 2021
The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy
MO Holmström, E Martinenaite, SM Ahmad, Ö Met, C Friese, L Kjær, ...
Leukemia 32 (2), 429-437, 2018
Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
HC Hasselbalch, MO Holmström
Seminars in Immunopathology 41 (1), 5-19, 2019
The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms
MO Holmström, CH Riley, IM Svane, HC Hasselbalch, MH Andersen
Leukemia 30 (12), 2413-2416, 2016
The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms
MO Holmström, MD Hjortsø, SM Ahmad, Ö Met, E Martinenaite, C Riley, ...
Leukemia 31 (2), 495-498, 2017
Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support: A study based on the nationwide Danish Myeloma …
MO Holmström, P Gimsing, N Abildgaard, NF Andersen, C Helleberg, ...
American journal of hematology 90 (4), E73-4, 2015
JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation
J Czech, S Cordua, B Weinbergerova, J Baumeister, A Crepcia, L Han, ...
Leukemia 33 (4), 995-1010, 2019
Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment
L Kjær, S Cordua, MO Holmström, M Thomassen, TA Kruse, N Pallisgaard, ...
PloS one 11 (10), e0165336, 2016
The Danish national multiple myeloma registry
P Gimsing, MO Holmström, TW Klausen, NF Andersen, H Gregersen, ...
Clinical epidemiology, 583-587, 2016
The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy
SM Ahmad, E Martinenaite, M Holmström, MA Jørgensen, Ö Met, ...
Oncoimmunology 7 (2), e1390641, 2018
High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals
MO Holmström, SM Ahmad, U Klausen, SK Bendtsen, E Martinenaite, ...
Blood cancer journal 9 (2), 8, 2019
Therapeutic cancer vaccination with a peptide derived from the calreticulin exon 9 mutations induces strong cellular immune responses in patients with CALR-mutant chronic …
J Handlos Grauslund, MO Holmström, NG Jørgensen, U Klausen, ...
Frontiers in Oncology 11, 637420, 2021
Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage …
MO Holmström, CH Riley, V Skov, IM Svane, HC Hasselbalch, ...
Oncoimmunology 7 (6), e1433521, 2018
Frequent adaptive immune responses against arginase-1
E Martinenaite, REJ Mortensen, M Hansen, M Orebo Holmström, ...
Oncoimmunology 7 (3), e1404215, 2018
Novel strategies for peptide-based vaccines in hematological malignancies
U Klausen, S Holmberg, MO Holmström, NGD Jørgensen, JH Grauslund, ...
Frontiers in immunology 9, 2264, 2018
Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients
ME Bjørn, MO Holmström, HC Hasselbalch
Leukemia & Lymphoma 57 (1), 125-128, 2016
Cancer immune therapy for Philadelphia chromosome-negative chronic myeloproliferative neoplasms
MO Holmström, HC Hasselbalch, MH Andersen
Cancers 12 (7), 1763, 2020
Sorted peripheral blood cells identify CALR mutations in B- and T-lymphocytes
L Kjaer, MO Holmström, S Cordua, MH Andersen, IM Svane, ...
Leukemia & lymphoma 59 (4), 973-977, 2018
Cancer immune therapy for myeloid malignancies: present and future
MO Holmström, HC Hasselbalch
Seminars in Immunopathology 41 (1), 97-109, 2019
Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer
MO Holmström, S Cordua, V Skov, L Kjær, N Pallisgaard, C Ellervik, ...
Cancer Immunology, Immunotherapy 69, 315-324, 2020
Sistema negali atlikti operacijos. Bandykite vėliau dar kartą.
Straipsniai 1–20